In a patient with disseminated intravascular coagulation (DIC) who has already received four units of packed red blood cells (PRBCs), one unit of fresh frozen plasma (FFP), and two units of cryoprecipitate, what are the recommended additional transfusion amounts of PRBCs, platelet units, FFP, and cryoprecipitate?

Transfusion Strategies in DIC

In DIC with active bleeding, transfuse platelets to maintain count >50 × 10⁹/L, FFP at 15-30 mL/kg, and cryoprecipitate (2 pools) if fibrinogen remains <1.5 g/L despite FFP; PRBCs are given based on hemodynamic need and hemoglobin targets, not fixed unit amounts. 1

Clinical Context and Approach

The transfusion strategy in DIC is fundamentally different from trauma protocols—you cannot use predetermined ratios. Transfusion decisions must be guided by serial laboratory monitoring and clinical bleeding status, not by counting units already given 1. The patient described has already received 4 PRBCs, 1 FFP, and 2 cryoprecipitate units, but this tells us nothing about what comes next without knowing current labs and bleeding status.

Platelet Transfusion Strategy

For active bleeding:

• Target platelet count >50 × 10⁹/L 1
• Transfuse 1-2 doses (typically 5-donor equivalent per dose) and recheck

For high bleeding risk (surgery/procedures) without active bleeding:

• Transfuse if platelets <30 × 10⁹/L in APL
• Transfuse if platelets <20 × 10⁹/L in other cancers 1

Critical caveat: Transfused platelets have very short lifespan in DIC due to ongoing consumption—expect to need frequent redosing 1

Fresh Frozen Plasma (FFP) Strategy

For active bleeding with prolonged PT/aPTT:

• Dose: 15-30 mL/kg 1
• For a 70 kg patient, this equals approximately 1000-2100 mL (4-8 units of FFP)
• Adjust based on clinical response and repeat coagulation studies
• Do not transfuse based on lab values alone without bleeding 2

If volume overload is a concern:

• Use prothrombin complex concentrates instead, though these only partially correct the defect 1, 2

Important: FFP is NOT indicated in DIC without bleeding 3. The evidence shows no benefit to prophylactic FFP transfusion and it does not stimulate ongoing coagulation activation 2.

Cryoprecipitate Strategy

Indication: Fibrinogen <1.5 g/L that persists despite FFP replacement in actively bleeding patients 1

Dose: 2 pools of cryoprecipitate (or fibrinogen concentrate if available) 1

Recheck fibrinogen after transfusion—consumption may be rapid and require additional doses.

PRBC Transfusion Strategy

There is no fixed unit amount for PRBCs in DIC. Unlike trauma protocols, DIC transfusion is not ratio-based. Transfuse PRBCs based on:

• Hemodynamic instability
• Ongoing blood loss
• Hemoglobin targets appropriate to the clinical context
• Tissue perfusion markers

The British guidelines emphasize that transfusion should not be based primarily on laboratory results but on clinical bleeding and hemodynamic status 2.

Algorithm for Ongoing Management

1. Recheck labs immediately: Platelets, PT/INR, aPTT, fibrinogen, hemoglobin
2. Assess bleeding status: Active bleeding vs. high risk vs. stable
3. If actively bleeding:
   • Platelets <50 × 10⁹/L → transfuse platelets (1-2 doses)
   • PT/aPTT prolonged → FFP 15-30 mL/kg
   • Fibrinogen <1.5 g/L after FFP → cryoprecipitate 2 pools
   • Hemoglobin/hemodynamics → PRBCs as needed
4. Recheck labs 1-2 hours after transfusion to guide further therapy
5. Repeat cycle as consumption continues

Critical Pitfalls to Avoid

• Do not use fixed ratios (like 1:1:1 trauma protocols)—DIC requires individualized, lab-guided therapy 1
• Do not transfuse prophylactically based on abnormal labs alone without bleeding 2, 3
• Do not forget the underlying cause—treating the trigger (sepsis, malignancy, etc.) is paramount 1, 2
• Expect rapid consumption—transfused products have shortened lifespan in DIC; frequent monitoring is essential 1
• Volume overload risk—large FFP volumes may necessitate switching to factor concentrates 1

Anticoagulation Consideration

If thrombosis predominates (venous thromboembolism, purpura fulminans, acral ischemia), consider therapeutic heparin even with abnormal coagulation studies, unless platelets <20 × 10⁹/L or active bleeding 2. For non-bleeding critically ill DIC patients, prophylactic LMWH is recommended 2.